NCX 470

Nicox Ophthalmics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	NCX 470
Also known as	nitric oxide (NO)-donating bimatoprost prostaglandin analog
Sponsor	Nicox Ophthalmics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (PHASE2, PHASE3)
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NCX 470 CI brief — competitive landscape report
NCX 470 updates RSS · CI watch RSS
Nicox Ophthalmics, Inc. portfolio CI